Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Cellcolabs Clinical AB
AB
Active
Org 5595011254
Scheeles Väg 5, 171 65
Solna
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2024 · 1 year old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Cellcolabs Clinical AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2025: 0M
0M
2025
EBITDA
SEK millions
0M
0M
0M
-1M
-1M
2025: 0M
0M
2025
Income statement
SEK thousands
Item
2025
Revenue
220
Staff expenses
—
EBITDA
10
Depreciation & amort.
—
EBIT
10
Net financials
−0
Profit before tax
10
Tax
−2
Net profit
8
Balance sheet
SEK thousands
Item
2025
Total assets
84
Equity
33
Long-term debt
—
Short-term debt
51
Total debt
51
Financial ratios
5-year trend
EBITDA margin
4,8 %
This company
15,8 %
Market median
This company
Market median
70% below market
2025
2025
Equity ratio
39,7 %
This company
38,2 %
Market median
This company
Market median
4% above market
2025
2025
Return on equity
24,7 %
This company
18,4 %
Market median
This company
Market median
34% above market
2025
2025
Net profit margin
3,7 %
This company
8,1 %
Market median
This company
Market median
54% below market
2025
2025
Asset turnover
2,63×
This company
1,12×
Market median
This company
Market median
135% above market
2025
2025
Debt / equity
1,52×
This company
0,62×
Market median
This company
Market median
145% above market
2025
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-10-21 – 2025-12-31
View
PDF
More on Cellcolabs Clinical AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
